Navigating Trip.com (TCOM) Stock – A Quick Overview

Large-cap Consumer Discretionary company Trip.com has logged a 6.2% change today on a trading volume of 1,008,291. The average volume for the stock is 3,894,003.

Trip.com Group Limited operates as a travel service provider for accommodation reservation, transportation ticketing, packaged tours and in-destination, corporate travel management, and other travel-related services in China and internationally. The company is now trading -17.46% away from its average analyst target price of $56.48 per share. The 27 analysts following the stock have set target prices ranging from $47.73 to $73.12, and on average give Trip.com a rating of buy.

Over the last 52 weeks, TCOM stock has risen 17.4%, which amounts to a -10.0% difference compared to the S&P 500. The stock's 52 week high is $47.45 whereas its 52 week low is $30.7 per share. With its net margins declining an average -2.0% over the last 6 years, Trip.com may not have a strong enough profitability trend to support its stock price.

Date Reported Total Revenue ($ k) Net Profit ($ k) Net Margins (%) YoY Growth (%)
2022 2,907,000 206,000 7 333.33
2021 3,142,000 -86,000 -3 83.33
2020 2,807,000 -497,000 -18 -190.0
2019 5,122,000 1,006,000 20 400.0
2018 4,524,000 162,000 4 -50.0
2017 4,146,287 329,221 8
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS